Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies
- PMID: 15541215
- DOI: 10.1007/s11934-004-0070-2
Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies
Abstract
The purpose of this review is to examine the biologic, pharmacologic, and clinical differences between the three currently approved phosphodiesterase-5 inhibitors to help the clinician make an educated choice about which medication may be best for any individual patient.
Similar articles
-
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.J R Soc Promot Health. 2003 Jun;123(2):79-80. doi: 10.1177/146642400312300209. J R Soc Promot Health. 2003. PMID: 12852189 No abstract available.
-
Phosphodiesterase 5 inhibitors in male sexual dysfunction.Curr Opin Urol. 2003 Sep;13(5):405-10. doi: 10.1097/00042307-200309000-00008. Curr Opin Urol. 2003. PMID: 12917517 Review.
-
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.Circulation. 2004 Nov 9;110(19):3149-55. doi: 10.1161/01.CIR.0000146906.42375.D3. Circulation. 2004. PMID: 15533876 Review. No abstract available.
-
Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.Expert Opin Pharmacother. 2005 Jan;6(1):1-2. doi: 10.1517/14656566.6.1.1. Expert Opin Pharmacother. 2005. PMID: 15709877 No abstract available.
-
Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.Am J Geriatr Cardiol. 2004 Nov-Dec;13(6):332-5. doi: 10.1111/j.1076-7460.2004.02725.x. Am J Geriatr Cardiol. 2004. PMID: 15538074 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical